Login to Your Account



Nabriva shares LEAP on pivotal CABP trial results

By Michael Fitzhugh
Staff Writer

Monday, September 18, 2017

A pivotal trial comparing lefamulin, Nabriva Therapeutics plc's antibiotic for patients with CABP, to the standard-of-care treatment, moxifloxacin, found it noninferior to the well-known quinolone.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription